Moderna’s COVID-19 booster gets TGA’s provisional approval

Be the First to Comment Read

Moderna’s COVID-19 booster gets TGA’s provisional approval

Moderna, Covid-19 Booster Shot, TGA approval, COVID-19, Vaccine
Image source: © Wachiwit | Megapixl.com

Highlights

  • Moderna's COVID-19 jab gets provisional approval from TGA.
  • Provisional approval is for use on Australians aged 18 and above.
  • ATAGI is now considering a final approval for Moderna’s vaccine.

Amidst the worrying Omicron surge, Australia’s TGA (Therapeutic Goods Administration) has given a provisional approval to Moderna’s COVID-19 vaccine for use as a booster shot in adults.

Which COVID-19 booster is available now?

  • At present, only Pfizer is vaccine stands approved as the booster vaccine for use in Australia. The green signal from TGA is a sign of Moderna’s vaccine soon getting added to the COVID-19 booster vaccine list.
  • According to Health Minister Greg Hunt Australia’s immunisation authority, ATAGI (Australian Technical Advisory Group), is to make a decision on the final clearance for Moderna’s vaccine use in the coming days.
  • The Federal government had purchased 25 million doses of Moderna’s vaccine, out of which around 15 million were to be used in H1-2022 as boosters.
  • The provisional approval, however, is only for use on Aussies aged eighteen and above. The Australians will thus soon have a choice between Pfizer and Moderna vaccine as a booster for immunity against the highly transmissible Omicron and previous COVID-19 variants.

How effective are booster shots against Omicron?

  • As of now, COVID-19 booster shots are available only for adults, after six months of second vaccine dose. ATAGI recently reviewed this booster time frame for growing worries from Omicron variant and kept it the same.
  • ATAGI in its review, could not find any proof of vaccine booster being more effective on Omicron with if given early.
  • Health Minister Greg Hunt is also hopeful that ATAGI will within a fortnight make its opinion on Moderna’s vaccine public.

From ASX: Broad-Based Gains & Fading Fears Of Omicron Push ASX 200 1% Higher

Also read: PlaySide (ASX:PLY) shares leap on deal with Shiba Inu Games

Disclaimer

Speak your Mind

Featured Articles

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK